| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Scientific Officer
1 company
Taveras Arthur serves as a Chief Scientific Officer at XFOR. Across recent SEC filings that breaks down to 0 buys and 6 sells. Those positions are worth an estimated $218K at current prices.
Historically, Taveras Arthur's trades have earned a middling insider score of 63/100 across 6 rated trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +39.0%.
The biggest single holding is XFOR (~$218K) as Chief Scientific Officer. The recent filings there lean toward selling, a net 177,371 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 7, 2024 | XFOR X4 Pharmaceuticals, Inc | Chief Scientific Officer | Sell | 76,920 | $0.56 | $43,305.96 | -16.5% | +40.0% | -78.3% | |
| Mar 11, 2024 | XFOR X4 Pharmaceuticals, Inc | Chief Scientific Officer | Sell | 14,235 | $0.88 | $12,552.42 | -5.7% | +13.9% | -65.1% | |
| Feb 12, 2024 | XFOR X4 Pharmaceuticals, Inc | Chief Scientific Officer | Sell | 787 | $1.01 | $792.67 | -0.3% | -4.3% | -54.0% | |
| Nov 1, 2023 | XFOR X4 Pharmaceuticals, Inc | Chief Scientific Officer | Sell | 67,695 | $0.73 | $49,417.35 | -21.4% | +6.8% | -33.4% | |
| Mar 10, 2023 | XFOR X4 Pharmaceuticals, Inc | Chief Scientific Officer | Sell | 16,806 | $0.84 | $14,117.04 | -16.3% | +142.9% | -0.6% | |
| Feb 13, 2023 | XFOR X4 Pharmaceuticals, Inc | Chief Scientific Officer | Sell | 928 | $0.93 | $863.04 | -0.9% | +60.9% | -2.6% |